Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
about
Protocol for a systematic review: understanding the motivations and barriers to uptake and use of female-initiated, primary biomedical HIV prevention technologies in sub-Saharan AfricaWomen's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South AfricaTowards preparedness for PrEP: PrEP awareness and acceptability among MSM at high risk of HIV transmission who use sociosexual media in four Celtic nations: Scotland, Wales, Northern Ireland and The Republic of Ireland: an online survey.HIV-AIDS: much accomplished, much to do.Disclosure of pharmacokinetic drug results to understand nonadherenceAdherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence.Perceived Advantages and Disadvantages of Using Pre-Exposure Prophylaxis (PrEP) among Sexually Active Black Women: An Exploratory Study.Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in ScotlandPerceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.Attitudes Towards PrEP and Anticipated Condom Use Among Concordant HIV-Negative and HIV-Discordant Male Couples.Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention.PEP and TasP Awareness among Italian MSM, PLWHA, and High-Risk Heterosexuals and Demographic, Behavioral, and Social CorrelatesIndividual HIV Risk versus Population Impact of Risk Compensation after HIV Preexposure Prophylaxis Initiation among Men Who Have Sex with Men.Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana.Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral releaseCombination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalisSilencing women's sexuality: global AIDS policies and the case of the female condomEvolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionParticipant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, KenyaCan a pill prevent HIV? Negotiating the biomedicalisation of HIV prevention.An expanded behavioral paradigm for prevention and treatment of HIV-1 infection.Measuring Transitions in Sexual Risk Among Men Who Have Sex With Men: The Novel Use of Latent Class and Latent Transition Analysis in HIV Sentinel Surveillance.Configuring the users of new HIV-prevention technologies: the case of HIV pre-exposure prophylaxis.Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies.Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States.The Role of Structural Barriers in Risky Sexual Behavior, Victimization and Readiness to Change HIV/STI-Related Risk Behavior Among Transgender Women.PrEP Implementation Science: State-of-the-Art and Research Agenda.The global HIV epidemic: current status and challenges.Women and ARV-based prevention: opportunities and challenges.Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women.Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.
P2860
Q26796724-871F4676-C167-4BDC-9BFB-3460FD75D06CQ28540042-43C87B7C-2D59-451C-B033-D076DB82C71BQ30196896-14A390FD-14ED-40FE-BCDF-A6C3B7EE3D51Q30354779-9F91A481-71B7-44BF-BE49-C283B681E3A8Q30674432-27B2F4FA-77F5-4ED7-8978-F4376FF9937FQ33765789-2CDEFD34-0D25-4CF6-8616-92DC35BE33E8Q33908319-05BFE7B2-E110-4987-8438-DA5D5060D831Q34180615-C3A9E90F-CD54-40AD-A15B-986DDFA3BF6CQ34573517-6F5630E7-6471-4D60-B2AF-61A47D66E0C0Q35561492-DC7B4E42-B595-4654-A622-86FB9DFA2896Q35857364-A9597411-7E14-4E45-AADE-04546BE30374Q35875733-C5747A89-CE8B-47A9-875A-01BAB5755057Q36050331-A603D695-872A-42EF-81AE-F9FB6A1A0891Q36242683-BCADEE6F-FF0B-4662-8E8E-92A519EE6458Q36451510-43C00FE6-B1E2-418C-B76C-87B895500892Q36666807-2CDC0D4C-6B00-4C6B-ACFC-95089908DFFBQ36816612-7B7FFB8F-15F7-4E7F-80B0-4D27ED45B6D8Q36997455-77783834-C8A6-4E41-BA93-6D571380F929Q37071435-65A245EE-A44E-4038-819C-748887DA039AQ37216377-4888C541-B234-4E54-9A95-DF3EBDA14199Q37388369-DB670D4A-774C-47C8-824E-EC3D748EE40EQ37404649-4CCB5249-AD59-43F9-ABAB-74DC83BC4328Q37618975-717A443E-9CEC-4B28-A19E-0AB57EA946FFQ37834595-F4913221-2FC0-4844-B8D0-191B12A1F283Q38255711-85A0AAA4-7877-407E-960D-B458A4CAB719Q38256787-FDAF6068-143A-4FE6-834F-7943679EAF91Q40062702-CFD6E5D5-AC3B-4832-A54B-740AB21919E3Q40612877-9A9913BE-85D0-453D-A911-FD3D1A7ADAB9Q40679190-E11589F5-C132-468F-BD44-58C3D788E0DEQ43241737-4ADE325A-0038-4105-B96E-0C4A3C981400Q43746712-016B34AE-488D-4041-B45F-D7CB651F8A6FQ46553256-C9816C86-7EBD-4B47-9A72-10F482F29B54Q52685409-A767C544-4202-418B-B81E-B84E30D6E0E4Q53837345-601F7F44-D0B2-4B74-AB0A-9EFD41F1EA35
P2860
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
@ast
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
@en
type
label
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
@ast
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
@en
prefLabel
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
@ast
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
@en
P2860
P1476
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
@en
P2093
Jared M Baeten
P2860
P2888
P304
P356
10.1007/S11904-013-0157-9
P577
2013-06-01T00:00:00Z